Female doctor shakes hands with a woman in nurse's uniform.

San Antonio Endovascular & Heart Institute first to deploy Biotricity’s new Bioflux remote monitoring device

Biotricity achieves commercial milestone ahead of schedule with first customer

APRIL 23, 2018 | BY BIOTRICITY

REDWOOD CITY, Calif., Apr. 23, 2018 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, today announced that the San Antonio Endovascular & Heart Institute (SAEHi) – a practice specializing in diagnosing, treating, managing, and researching diseases and disorders of the heart and vascular system – deployed Biotricity’s Bioflux on April 6, 2018. SAEHi will leverage the real-time, high-precision mobile cardiac telemetry solution to assist in the diagnosis of cardiac arrhythmias, enhance patient outcomes, improve patient compliance, and curb healthcare costs.

The Institute is headed by President and CEO Dr. R. Stefan Kiesz, a world-renowned interventional cardiologist who commented, “I love the simplicity the Bioflux technology provides for my patients, which should encourage greater compliance and improved data collection. The device fit seamlessly with our practice and didn’t interrupt our workflow whatsoever, in fact, it streamlined it. I’m also optimistic and excited about the prospects and applications of this platform in other medical markets serving outpatient treatments, and I believe this technology should be considered for post percutaneous coronary intervention (PCI).”

The Bioflux system is designed to be a complete solution for cardiac monitoring and diagnosis, consisting of the Bioflux device, proprietary software, and a 24/7 monitoring center that merges seamlessly with physicians’ existing platforms and workflows. Unlike traditional cardiac monitoring solutions, Bioflux extends the support a patient receives at a care facility into the patient’s home. The device monitors a patient’s ECG in near real-time, constantly analyzing and collecting data on the device and periodically uploading to the cloud via embedded cellular technology.

“Bioflux helps healthcare professionals, like SAEHi, leverage advanced technology to transmit data as it happens,” said Dr. Bartlomiej Gora, clinical research coordinator at the Institute. “This not only facilitates data analysis and integration into our workflow, but also allows the patient to be diagnosed at home and to feel safer. At the end of the day, we are improving our patient-consumer outcomes because Bioflux provides actionable data and feedback.”

“We are thrilled to see our new solution at work with San Antonio Endovascular & Heart Institute, as they continue to build their reputation as an unparalleled innovator in heart disease diagnosis and treatment,” said Mr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. “Bioflux was purposely built for cardiac patients who require active monitoring because, until now, short-term monitoring or admission into the hospital for long-term observation was the most accessible option.”

To learn more, visit www.biotricity.com or follow on

Twitter: @biotricity_inc Facebook: www.facebook.com/biotricity/ or
LinkedIn: www.linkedin.com/company/biotricity-measuring-vitals

About Biotricity Inc.

Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts:

Media contacts

McCoin & Smith Communications Inc.

Chris McCoin
Chris@mccoinsmith.com
508-429-5988

Richard Smith
Rick@mccoinsmith.com
978-433-3304

Investor relations:

Biotricity Investor Relations
Investors@biotricity.com
1.800.951.3348